Navigation Links
UBC researchers identify potential new therapy approach for hepatitis C
Date:1/15/2012

Researchers at the University of British Columbia have found a new way to block infection from the hepatitis C virus (HCV) in the liver that could lead to new therapies for those affected by this and other infectious diseases.

More than 170 million people worldwide suffer from hepatitis C, the disease caused by chronic HCV infection. The disease affects the liver and is one of the leading causes of liver cancer and liver transplant around the world. HCV is spread by blood-to-blood contact and there is no vaccine to prevent it. Current treatments for the disease are only moderately effective and can cause serious side effects.

"As HCV infects a person, it needs fat droplets in the liver to form new virus particles," says Franois Jean, Associate Professor in the Department of Microbiology and Immunology and Scientific Director of the Facility for Infectious Disease and Epidemic Research (FINDER) at UBC. "In the process, it causes fat to accumulate in the liver and ultimately leads to chronic dysfunction of the organ."

"HCV is constantly mutating, which makes it difficult to develop antiviral therapies that target the virus itself," says Jean. "So we decided to take a new approach."

Jean and his team developed an inhibitor that decreases the size of host fat droplets in liver cells and stops HCV from "taking residence," multiplying and infecting other cells.

"Our approach would essentially block the lifecycle of the virus so that it cannot spread and cause further damage to the liver," says Jean. The team's method is detailed in the journal PLoS Pathogens.

According to Jean, HCV is one of a number of viruses that require fat to replicate in the human body. This new approach to curbing the replication of HCV could translate into similar therapies for other related re-emerging viruses that can cause serious and life threatening infections in humans, such as dengue virus. Dengue is endemic in more than 100 countries, with approximately 2.5 billion people at risk of infection globally. In some countries, Dengue has become the leading cause of child mortality.


'/>"/>
Contact: Brian Lin
brian.lin@ubc.ca
604-822-2234
University of British Columbia
Source:Eurekalert

Related medicine news :

1. Researchers map all the fragile sites of the yeast Saccharomyces cerevisiaes genome
2. UH Case Medical Center researchers publish promising findings for advanced cervical cancer
3. Researchers discover new way to kill pediatric brain tumors
4. Researchers Who Discovered First Genes for Stuttering will Present Findings to the National Stuttering Association
5. Researchers create drug to keep tumor growth switched off
6. Urine protein test might help diagnose kidney damage from lupus, UT Southwestern researchers find
7. GUMC researchers say flower power may reduce resistance to breast cancer drug tamoxifen
8. Clemson researchers develop hands-free texting application
9. Researchers find biomarkers in saliva for detection of early-stage pancreatic cancer
10. Researchers chart genomic map spanning over 2 dozen cancers
11. Researchers discover second protective role for tumor-suppressor
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... , ... December 05, 2016 , ... ... it has been featured in SuperbCrew magazine, a leading online tech news platform ... This interview, now featured on SuperbCrew.com, explores the state of enterprise mobility security ...
(Date:12/5/2016)... ... December 05, 2016 , ... ... today that nominations will be accepted from December 5, 2016 through March ... Awards include the Information Security Executive® of the Year, which recognizes executives ...
(Date:12/5/2016)... ... December 05, 2016 , ... Researchers at Johns Hopkins All ... brains of young athletes. Over the course of three years, researchers will study concussions ... guards. The mouth guards, equipped with special sensors, will track the location and force ...
(Date:12/5/2016)... ... December 05, 2016 , ... Worldwise ®, a leading ... firm kathy ireland® Worldwide for five additional years, announced by Kevin Fick, Worldwise ... licensing agreement three years ago to design and develop the kathy ireland® Loved ...
(Date:12/5/2016)... ... December 05, 2016 , ... “Epilepsy Awareness,” which can be ... sparks a conversation about epilepsy, bearing down on the social stigma and lack ... diagnosed with epilepsy within their lifetime. With such a large percentage of people ...
Breaking Medicine News(10 mins):
(Date:12/5/2016)... Israel , December 5, 2016 ... identifying, in-licensing and developing promising therapeutic candidates, presents positive Phase ... BL-8040, the Company,s leading oncology platform at the ongoing 58th ... San Diego, California . ... , , ...
(Date:12/5/2016)... TAIPEI, Taiwan , Dec. 5, 2016 ... showed non-inferiority to hydroxyurea (HU) in Complete Hematologic Response (CHR) ... tolerability profile of ropeginterferon alfa-2b versus HU ... long-term follow-up trial CONTINUATION-PV to obtain European marketing authorization in ... this data to the FDA as it seeks approval for ...
(Date:12/4/2016)... HOUSTON , Dec. 3, 2016   Pairnomix, LLC, ... Precision Medicine Alliance (PEPMA) recognized by the White House, today ... individualized approach to the identification of candidate therapies for a ... SCN8A gene were presented at the 70 th ... in Houston, TX , December 2-6, 2016.  ...
Breaking Medicine Technology: